Digital Understanding the prevention and treatment needs for cardiov... What does the current picture of cardiovascular disease in Europe look like?
Digital The rise, acceleration and acceptance of telehealth adoption ‘Healing at a distance’ is the literal meaning of telemedicine.
Digital Targeted agents and immunotherapies Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment.
Digital An open call for innovation There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains.
News Novo Nordisk obesity drug linked to rare cause of sight loss The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
